David Weill Sells 5,000 Shares of TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director David Weill sold 5,000 shares of TransMedics Group stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the sale, the director directly owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

TransMedics Group Stock Performance

NASDAQ TMDX traded down $2.12 on Friday, reaching $136.51. The stock had a trading volume of 462,535 shares, compared to its average volume of 1,213,045. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The company has a market cap of $4.66 billion, a P/E ratio of 55.27 and a beta of 2.06. The firm has a fifty day moving average of $124.55 and a two-hundred day moving average of $122.75. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. During the same quarter last year, the firm earned $0.12 earnings per share. The company’s revenue was up 32.2% on a year-over-year basis. On average, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Institutional Investors Weigh In On TransMedics Group

Large investors have recently modified their holdings of the business. Opal Wealth Advisors LLC acquired a new position in shares of TransMedics Group during the 2nd quarter worth $26,000. Whittier Trust Co. of Nevada Inc. grew its position in TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after acquiring an additional 206 shares during the last quarter. Salomon & Ludwin LLC bought a new position in TransMedics Group in the third quarter valued at about $28,000. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group during the third quarter worth about $29,000. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after acquiring an additional 135 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TMDX. Piper Sandler decreased their target price on shares of TransMedics Group from $145.00 to $140.00 and set an “overweight” rating on the stock in a research report on Thursday, October 30th. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Stifel Nicolaus began coverage on TransMedics Group in a research note on Thursday, September 4th. They set a “hold” rating and a $115.00 price objective on the stock. Canaccord Genuity Group upped their target price on TransMedics Group from $142.00 to $147.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, Needham & Company LLC reissued a “buy” rating on shares of TransMedics Group in a report on Thursday, October 30th. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $133.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.